The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers
The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers
复制标题
DOI：
10.1002/jso.20426
复制
发表时间：
2006-01-01
影响因子：
2.5
通讯作者：
Mori, M
中科院分区：
文献类型：
--
作者：
Mimori, K;Nagahara, H;Mori, M
背景和目的：最近的研究发现，非小细胞肺癌(NSCLC)中存在表皮生长因子受体(EGFR)基因的体细胞突变，而EGFR酪氨酸激酶抑制剂(Gefitinib)的易感性取决于该基因激动域的突变。因此，我们预测了吉非替尼对12%的原发结直肠癌的临床益处，该突变反映了这种潜在的独特易感性。患者和方法：在不同的原发癌症中，EGFR中的激动域的突变状态具有重要的临床意义，因为突变的存在被认为是吉非替尼治疗有效性的可靠指标。在本研究中，我们调查了5个胃癌细胞系和39个原发胃癌及其相应的正常组织中编码ATP结合域的第18-21外显子的体细胞突变。结果和结论：EGFR的激动域在所有胃癌细胞系和病例中高度保守，因此不幸的是，吉非替尼不被推荐用于此类恶性肿瘤的治疗。
Background and Objectives: Recent studies have disclosed the presence of somatic mutations in the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC), and susceptibility to the EGFR tyrosine kinase inhibitor (gefitinib) was determined by the presence of mutations in the kinase domain of this gene. We thus predicted a clinical benefit of gefitinib against the 12% of primary colorectal cancers exhibiting a mutation reflective of this potential distinctive susceptibility.Patients and Methods: The mutation status of the kinase domain in EGFR in different primary cancers has important clinical consequences, because the presence of a mutation is recognized as a reliable indicator for the effectiveness of gefitinib administration. In the current study, we investigated the presence of somatic mutations in exons 18-21 coding the ATP-binding domain in five gastric cancer cell lines and 39 primary gastric cancers and their corresponding normal tissues.Results and Conclusions: The kinase domain of EGFR is highly conserved in whole gastric cancer cell lines and cases, therefore treatment with gefitinib is unfortunately not recommended for such malignancy.